Skelaxin (cyclobenzaprine) vs. Methocarbamol – A quick comparison
| Feature | Skelaxin (cyclobenzaprine) | Methocarbamol |
|---------|----------------------------|---------------|
| Drug class | Centrally acting muscle relaxant; structurally a tricyclic antidepressant (TCA). | Centrally acting muscle relaxant; exact mechanism is unclear, but likely GABA‑modulating. |
| Typical indications | Short‑term relief of acute musculoskeletal pain, muscle spasms, and related tension. | Same—short‑term relief of acute musculoskeletal pain and muscle spasm. |
| Common brand names | Skelaxin (US), Flexeril, Levetex (global). | No major brand names in the US; often sold generically. |
| Dose (adult) | 5 mg TID → up to 10 mg TID (max 10 mg qid); start low, titrate up. | 250–500 mg qid (max 3000 mg/day); start low, increase to a maximum tolerated dose. |
| Onset of action | 1–2 hours (peak 3–5 hrs). | 30–60 minutes (peak ~2 hrs). |
| Duration of action | 12–24 hrs (longer half‑life ~18 hrs). | 4–6 hrs (shorter half‑life ~5 hrs). |
| Pharmacokinetics | Metabolized in liver via CYP1A2 and CYP3A4. Metabolites are inactive. | Metabolized by hepatic and renal pathways; excreted largely unchanged in urine. |
| Common side effects | Drowsiness, dizziness, dry mouth, constipation, mild sedation. Anticholinergic effects (blurred vision, urinary retention) can appear at higher doses. | Drowsiness, dizziness, nausea, vomiting, mild sedation. Less anticholinergic. |
| Drug interactions | Stronger risk with MAO inhibitors, SSRIs, SNRIs, other CNS depressants, alcohol. May increase seizure risk with certain anticonvulsants. | Interacts with CNS depressants (benzodiazepines, opioids, alcohol). Can increase CNS depression. |
| Contraindications | MAO inhibitors, pregnancy (category C), severe renal/hepatic impairment, known sensitivity. | Pregnancy (category B), breastfeeding, severe hepatic or renal impairment. |
| Special considerations | TCA core can affect heart conduction (rare). Monitor blood pressure and heart rate in patients with cardiac disease. | Less cardiac effect; but can potentiate other CNS depressants. |
| Cost & availability | Usually inexpensive (generic). | Typically inexpensive but less widely prescribed; check local formulary. |
---
What the differences mean in practice
| Issue | Skelaxin (cyclobenzaprine) | Methocarbamol |
|-------|---------------------------|---------------|
| Effect on alertness | Stronger sedative effect, especially at the higher end of the dose range. | Sedation is present but generally milder. |
| Anticholinergic burden | Present (dry mouth, constipation, urinary retention). | Minimal. |
| Metabolism risk | CYP3A4 inhibitors (e.g., clarithromycin) or inducers (e.g., rifampin) can alter levels. | Less dependence on CYP enzymes, so fewer drug‑drug interactions via that route. |
| Use with alcohol/CNS depressants | Both should be avoided with alcohol; cyclobenzaprine is especially risky with benzodiazepines or opioids. | Same caution, but because methocarbamol’s sedation is less pronounced, some clinicians prefer it when co‑prescribing opioids. |
| Pregnancy | Category C; use only if benefits outweigh risks. | Category B; safer profile in pregnancy. |
---
When might you pick one over the other?
| Situation | Preferred choice |
|-----------|-----------------|
| Patient already on serotonergic antidepressants | Methocarbamol (to avoid serotonin‑syndrome risk with cyclobenzaprine). |
| Patient with a history of dry mouth or constipation | Methocarbamol (lower anticholinergic burden). |
| Patient on strong CYP3A4 inhibitors (e.g., clarithromycin) | Methocarbamol (less CYP‑mediated metabolism). |
| Patient needs a longer‑acting muscle relaxant | Skelaxin (longer half‑life). |
| Patient is elderly with mild hepatic impairment | Methocarbamol (less hepatic metabolism). |
| Patient is on opioids for pain | Often methocarbamol is chosen to avoid additive sedation, but if the patient tolerates cyclobenzaprine, it can still be used. |
---
Bottom line
Both Skelaxin (cyclobenzaprine) and methocarbamol are first‑line agents for acute muscle spasm and associated pain. The choice usually depends on:
1. Patient’s comorbidities and current meds – look out for anticholinergic load and CYP‑mediated interactions.
2. Side‑effect tolerability – cyclobenzaprine is more sedating and anticholinergic; methocarbamol is milder in those respects.
3. Desired duration of action – cyclobenzaprine stays longer in the system.
4. Pregnancy or lactation status – methocarbamol has a slightly better safety record.
Always consult your healthcare provider before starting or switching between these agents, especially if you’re on other CNS‑active medications, have cardiac or hepatic concerns, or are pregnant/breast‑feeding.